HYPERION DEFI, INC.
HYPD evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $54.2M
- Lead Asset:
- clobetasol propionate ophthalmic suspension 0.05% (Approved)
What it means
What to watch
Prepared research question
What matters most for HYPD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HYPD
HYPERION DEFI, INC. (HYPD) is a biopharmaceutical company developing ophthalmic therapies using its Optejet drug-delivery platform, with a focus on pediatric myopia, post-operative inflammation, and presbyopia.
Key risk: Accumulated deficit
BioSniper Score
Based on 5 of 6 signals
Market Cap
$54.2M
Cash Runway
—
Lead Asset
clobetasol propionate ophthalmic suspension 0.05% (Approved)
Next Catalyst
Patent_Expiry · Jul 15, 2031Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 catalyst for HYPERION DEFI, INC..
HYPERION DEFI, INC. (HYPD) is a biopharmaceutical company developing ophthalmic therapies using its Optejet drug-delivery platform, with a focus on pediatric myopia, post-operative inflammation, and presbyopia.
- Cash and equivalents of $9.6M as of 2026-06-30 [sec].
- Total revenue of $0.4M and net income of $31.0M as of 2026-06-30 [sec].
- Shareholders' equity of $101.9M and total debt of $14.1M as of 2026-06-30 [sec].
- Lead candidate MicroPine (low-dose atropine) for pediatric myopia is in preclinical phase with two competitors in Phase 3 [pipeline].
- Clobetasol propionate ophthalmic suspension 0.05% for post-operative inflammation is approved [pipeline].
What works
- Clobetasol propionate ophthalmic suspension 0.05% is already approved, providing a commercial product [pipeline].
- MicroPine has a partnership with Bausch + Lomb and Arctic Vision, indicating external validation and potential market access [pipeline].
- The company has a positive net income of $31.0M as of 2026-06-30, suggesting recent profitability [sec].
What to weigh
- As of September 30, 2025, the company had an accumulated deficit of approximately $200.9 million [sec · filed 2025-12-10].
- The company requires significant capital and may need to raise additional capital on acceptable terms to continue operations [sec · filed 2025-12-10].
- MicroPine is still in preclinical phase with two competitors already in Phase 3, indicating a competitive lag [pipeline].
- Cash and equivalents decreased from $8.2M as of September 30, 2025 [sec · filed 2025-12-10] to $9.6M as of June 30, 2026 [sec], but the company had $8.2M in debt under a Loan and Security Agreement as of September 30, 2025 [sec · filed 2025-12-10].
From the filings
Quoted directly from source documents.
Accumulated deficit as of September 30, 2025
“we had cash and cash equivalents of $8.2 million and an accumulated deficit of approximately $200.9 million”
SEC filings · December 10, 2025
Clobetasol propionate ophthalmic suspension 0.05% is approved
“Indication: post-operative inflammation and pain after ocular surgery Phase: Approved”
MicroPine is in preclinical phase
“Phase: Preclinical”
Catalyst timeline
- 2031-07-15 · Patent_Expiry · PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE — Patent_Expiry: NDA215352 — Patent expiry for phenylephrine hydrochloride and tropicamide may open generic competition, but relevance to current pipeline is unclear.
Risks & what to watch (4)›
Key risks
- Accumulated deficit — Accumulated deficit of ~$200.9M as of Sep 30, 2025 [sec · filed 2025-12-10]
- Capital dependency — Requires significant capital; may need to raise additional funds on acceptable terms [sec · filed 2025-12-10]
- Competitive lag in myopia — MicroPine preclinical while two competitors are in Phase 3 [pipeline]
- Debt obligation — Owed $8.2M in principal and accrued interest under Loan and Security Agreement as of Sep 30, 2025 [sec · filed 2025-12-10]
What to watch
- Progress of MicroPine through preclinical development and potential FDA interactions [sec · filed 2024-01-16]
- Ability to raise additional capital to fund operations and HYPE reserve [sec · filed 2025-12-10]
- Commercial performance of approved clobetasol propionate product [pipeline]
- Outcome of CHAPERONE pediatric myopia study and regulatory pathway [sec · filed 2024-01-16]
Sources: Pipeline · SEC filings · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run HYPERION DEFI, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HYPERION DEFI, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.11 · 20% dilution
Lead: Approved
5 candidates
1 upcoming, next in ~1735d
4 buys · 0 sells (180d)
Catalysts
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 9.5%
- Days to cover
- 3.0
- Shares short
- 1,040,944
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HYPD short interestGovernance
Frequently asked questions
What is the AI investment thesis for HYPERION DEFI, INC.?
HYPERION DEFI, INC. (HYPD) is a biopharmaceutical company developing ophthalmic therapies using its Optejet drug-delivery platform, with a focus on pediatric myopia, post-operative inflammation, and presbyopia.
What is HYPERION DEFI, INC.'s lead drug candidate?
HYPERION DEFI, INC.'s most advanced tracked candidate is clobetasol propionate ophthalmic suspension 0.05% (Approved) for post-operative inflammation and pain after ocular surgery.
What is HYPERION DEFI, INC.'s next catalyst?
HYPERION DEFI, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA215352" — expected July 15, 2031.
Who is the CEO of HYPERION DEFI, INC.?
Mr. Hyunsu Jung is the chief executive officer of HYPERION DEFI, INC. (HYPD).
Where is HYPERION DEFI, INC. headquartered?
HYPERION DEFI, INC. (HYPD) is headquartered in Dallas, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.